Compare Recursion Pharmaceuticals Inc (RXRX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B), while Sirius XM Holdings Inc trades at $28.56 (market cap $9.70B). The key difference: Sirius XM Holdings Inc is far larger — about 5.4× Recursion Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SIRI | |
|---|---|---|
Market Cap | $1.81B | $9.70B |
Sector | Health | Media |
52-Week High | $6.79 | $32.59 |
52-Week Low | $2.84 | $19.92 |
Enterprise Value | $1.33B | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SIRI trades at $28.78, down 3.78% today, reflecting a bearish technical signal amid mixed earnings. The stock shows modest revenue growth and strong cash flow, with a P/E of 11.56 and P/B of 0.81 indicating potential undervaluation. Recent Q2 2026 earnings missed estimates, but the company raised full-year guidance, highlighting stable subscriber metrics and a dividend payout.
The outlook is cautiously optimistic, supported by analyst consensus of $33.17 price target and 58% buy ratings. Key risks include competitive pressures in satellite radio and high debt levels, though declining leverage and share buybacks offer upside. Investors should weigh stable cash generation against growth challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
